Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;51(3):1135-1137.
doi: 10.1007/s42770-020-00246-9. Epub 2020 Mar 20.

Evaluation of the susceptibility test of polymyxin B using the commercial test Policimbac®

Tanise Vendruscolo Dalmolin  1   2 , Maiara Dos Santos Carneiro  1   2 , Luíza Peres de Castro  1 , Fabiana Caroline Zempulski Volpato  1   3 , Priscila Lamb Wink  1   2 , Daiana de Lima-Morales  1 , Afonso Luís Barth  4   5   6
Affiliations

Evaluation of the susceptibility test of polymyxin B using the commercial test Policimbac®

Tanise Vendruscolo Dalmolin et al. Braz J Microbiol. 2020 Sep.

Abstract

Broth microdilution (BMD), the reference method to determine bacterial susceptibility to polymyxins, is a laborious and time-consuming technique. Policimbac® is a commercial test panel which uses lyophilized polymyxin B to determine the minimum inhibitory concentration for Gram-negative isolates. This study evaluated the performance of Policimbac® in comparison with BMD for 110 isolates. Although the Policimbac® presented a very low essential agreement, the categorical agreement with BMD was optimal. Policimbac® is an alternative approach to BMD for evaluating the susceptibility to polymyxin B.

Keywords: Antimicrobial resistance; Policimbac®; Polymyxin B; Polymyxins.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333–1341. doi: 10.1086/429323. - DOI - PubMed
    1. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol. 2009;47:1611–1612. doi: 10.1128/JCM.02466-08. - DOI - PMC - PubMed
    1. Nordmann P, Jayol A, Poirel L. Rapid detection of polymyxin resistance in Enterobacteriaceae. Emerg Infect Dis. 2016;22:1038–1043. doi: 10.3201/eid2206.151840. - DOI - PMC - PubMed
    1. Rahal JJ. The role of carbapenems in initial therapy for serious gram-negative infections. Crit Care. 2008;12(4):S5–S7. doi: 10.1186/cc6821. - DOI - PMC - PubMed
    1. Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in gram-negative organisms. Int J Antimicrob Agents. 2017;49:526–535. doi: 10.1016/j.ijantimicag.2016.11.029. - DOI - PubMed

Publication types

MeSH terms